Medical students' exposure to and attitudes towards product promotion and incentives from the pharmaceutical industry in 2019: a national cross-sectional study in France.

ethics (see medical ethics) health policy medical education & training organisation of health services quality in health care

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 07 2022
Historique:
entrez: 20 7 2022
pubmed: 21 7 2022
medline: 23 7 2022
Statut: epublish

Résumé

To measure medical students' exposure to pharmaceutical product promotion and incentives nationwide, and to evaluate students' attitudes towards the pharmaceutical industry, access to education on promotional strategies and knowledge of institutional policies about drug company-student relationships. Cross-sectional survey based on a 48-item anonymous questionnaire. All 37 French medical schools, from March to April 2019. French medical students in their 4th year of study and beyond, having studied exclusively in France. Cumulative frequency of students' exposure to pharmaceutical product promotion and incentives. Exposure within the last 6 months, attitudes regarding interactions with the industry, access to education on pharmaceutical product promotion and incentives and knowledge of institutional policies. 6280 responses were analysed (10.4% out of a total of 60 550 eligible students). 5992 students (96.3% poststratification, 99% CI (96.1% to 96.5%)) had already been exposed to pharmaceutical product promotion and incentives and 4650 (78.1%, 99% CI (77.7% to 78.6%)) within the last 6 months. 5140 students (85.4%, 99% CI (84.8% to 85.8%)) had met a pharmaceutical representative. Regarding attitudes, 2195 students (36.8%, 99% CI (36.0% to 37.5%)) thought receiving a gift could influence their own prescriptions while 3252 (53.6%, 99% CI (53.1% to 54.2%)) thought it could influence their colleagues' prescriptions. 4533 students (76.0%, 99% CI (75.6% to 76.5%)) reported never having attended any lecture on promotional strategies. Exposure seemed to depend on the year of study and specialty. 5122 (88.1%, 99% CI (87.7% to 88.4%)) did not know whether their faculty had a policy regarding drug company-student interactions. In France in 2019, medical students' exposure to pharmaceutical product promotion and incentives remains considerable and starts early during medical training. Education on promotional strategies and institutional policies should be improved to ensure responsible and ethical behaviour in prescribing medications.

Identifiants

pubmed: 35858728
pii: bmjopen-2020-045671
doi: 10.1136/bmjopen-2020-045671
pmc: PMC9305804
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e045671

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and made the following declarations: MM reported one meal financed by a drug company in 2016. AB reported several meals financed by drug companies between 2016 and 2017. ME reported no competing interest. BB is employed by University of Rennes 1, at Rennes Medical School, as a senior lecturer, but did not receive any specific benefit for this work; there were no other financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; there were no other relationships or activities that could be considered to have influenced the submitted work.

Références

J Fam Pract. 1987 Jun;24(6):612-6
pubmed: 3585265
WMJ. 2010 Jun;109(3):142-8
pubmed: 20672554
Cochrane Database Syst Rev. 2017 Feb 16;2:MR000033
pubmed: 28207928
JAMA. 2005 Sep 7;294(9):1034-42
pubmed: 16145023
JAMA. 2000 Jan 19;283(3):373-80
pubmed: 10647801
CMAJ. 2003 Sep 2;169(5):405-12
pubmed: 12952801
PLoS One. 2014 Mar 26;9(3):e92858
pubmed: 24671179
PLoS One. 2017 Apr 13;12(4):e0175493
pubmed: 28406971
JAMA Intern Med. 2014 Aug;174(8):1283-90
pubmed: 24911123
JAMA. 2001 Oct 24-31;286(16):1994-9
pubmed: 11667936
PLoS One. 2017 Jan 9;12(1):e0168258
pubmed: 28068362
Lancet. 2011 Mar 12;377(9769):890-2
pubmed: 21409784
N Engl J Med. 2007 Apr 26;356(17):1742-50
pubmed: 17460228
Med J Aust. 2011 Feb 7;194(3):121-5
pubmed: 21299485
Acad Med. 2004 Nov;79(11):1041-5
pubmed: 15504768
PLoS One. 2019 Nov 1;14(11):e0224193
pubmed: 31675383
PLoS One. 2013 Jul 04;8(7):e68633
pubmed: 23861928
Arch Intern Med. 2009 May 11;169(9):887-93
pubmed: 19433701
JAMA. 2003 Jul 9;290(2):252-5
pubmed: 12851281
Chest. 1992 Jul;102(1):270-3
pubmed: 1623766
BMJ. 2007 May 19;334(7602):1020
pubmed: 17510114
BMJ. 2013 Jan 30;346:f264
pubmed: 23372175
Pers Soc Psychol Bull. 1988 Jun;14(2):264-270
pubmed: 30045472
PLoS Med. 2011 May;8(5):e1001037
pubmed: 21629685
Int J Clin Pharmacol Ther Toxicol. 1984 Jun;22(6):279-83
pubmed: 6746151
Acad Med. 2015 Aug;90(8):1137-46
pubmed: 25785675
BMJ. 2019 Nov 5;367:l6015
pubmed: 31690553
Am J Med. 1982 Jul;73(1):4-8
pubmed: 7091173
PLoS Med. 2010 Oct 19;7(10):e1000352
pubmed: 20976098
Med Care. 2013 Feb;51(2):199-203
pubmed: 23142772
BMC Med Educ. 2016 Aug 12;16(1):202
pubmed: 27519253
Eur J Clin Pharmacol. 2010 Jul;66(7):727-33
pubmed: 20300742

Auteurs

Martin Molina (M)

Department of General Practice, Univ Rennes, Rennes, France.

Adeline Boëffard (A)

Department of General Practice, Univ Rennes, Rennes, France.

Maxime Esvan (M)

Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France.

Benjamin Bastian (B)

Department of General Practice, Univ Rennes, Rennes, France benjamin.bastian@univ-rennes1.fr.
Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH